

Diffuse Large B-Cell Lymphoma (DLBCL)

**A Study Evaluating the Safety and Efficacy of RO7082859 or Mosunetuzumab (RO7030816) in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma**

**Trial Status**  
Completed

**Trial Runs In**  
0 Countries

**Trial Identifier**  
NCT04313608 GO41943

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

This study is designed to evaluate the safety and efficacy of glofitamab or mosunetuzumab in combination with gemcitabine and oxaliplatin (Glofit-GemOx or Mosun-GemOx) in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL).

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT04313608 GO41943**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No

---